Sejin Lee

US Food and Drug Administration Officials’ Public Statements on Regulatory Flexibility in New Drug Approval, 2021–2024

The US Food and Drug Administration (FDA) has historically exercised substantial regulatory flexibility to adjust the type, amount, and quality of evidence necessary to support drug approval for areas of unmet need. Our objective was to characterize how FDA officials described an...